Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: A clinicopathologic study

Gynecologic Oncology

Volumn 98, Issue 3, 2005, Pages 396-402

  Brustmann, Hermann ^a  

^a Thermenklinikum ^*  (Austria)

Author keywords

c kit; Grade; Human telomerase reverse transcriptase (hTERT); Mitotic activity; Outcome; Prognosis; Serous ovarian carcinoma; Stage

Indexed keywords

FORMALDEHYDE; PARAFFIN; STEM CELL FACTOR; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER GRADING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTADENOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MITOSIS; OUTCOMES RESEARCH; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE SECTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL RATE; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 23844447668     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.04.035     Document Type: Article

References (32)

1. C.B. Harley, A.B. Futcher, and C.W. Greider Telomeres shorten during aging of human fibroblasts Nature 345 1990 458 460
2. J.Y. Yoo, S.Y. Park, S.J. Kang, B.K. Kim, S.I. Shim, and C.S. Kang Expression of telomerase activity, human telomerase RNA, and telomerase reverse transcriptase in gastric adenocarcinomas Mod. Pathol. 16 2003 700 707
3. F. Kumaki, T. Kawai, S. Hiroi, N. Shinomiya, Y. Ozeki, and V.J. Ferrans Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas Hum. Pathol. 23 2001 188 195
4. S. Kyo, K. Masutomi, Y. Maida, T. Kanaya, N. Yatabe, and M. Nakamura Significance of immunological detection of human telomerase reverse transcriptase Am. J. Pathol. 163 2003 859 867
5. M. Meyerson, C.M. Counter, E.N. Eaton, L.W. Ellisen, P. Steiner, and S.D. Caddle hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization Cell 90 1997 785 795
6. S.L. Weinrich, R. Pruzan, L. Ma, M. Ouellette, V.M. Tesmer, and S.E. Holl Reconstitution of human telomerase with template RNA component hTERC and the catalytic protein subunit hTERT Nat. Genet. 17 1997 498 502
7. G. Bonatz, S.O. Frahm, W. Klapper, A. Helfenstein, K. Heidorn, and W. Jonat High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus Hum. Pathol. 32 2001 605 614
8. Y. Yarden, W.S. Kuang, T. Yang-Feng, L. Coussens, S. Munemitsu, and T.J. Dull Human proto-oncogene, c-kit, a new cell surface receptor tyrosine kinase for an unidentified ligand EMBO J. 6 1987 3341 3351
9. J.V. Scobie, G. Acs, C.A. Bandera, S.V. Blank, J.E. Wheeler, and T.L. Pasha C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance Int. J. Gynecol. Pathol. 22 2003 149 155
10. R.E. Schmandt, R. Broaddus, K.H. Lu, H. Shvartsman, A. Thornton, and A. Malpica Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium Cancer 98 2003 758 764
11. S.J. Hines, C. Organ, M.J. Kornstein, and G.W. Krystal Coexpression of the c-kit and stem cell factor genes in breast carcinomas Cell Growth Differ. 6 1995 769 779
12. G.W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger The selective tyrosine kinase inhibitor ST1571 inhibits small cell lung cancer growth Clin. Cancer Res. 6 2000 3319 3326
13. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. van den Abbeele, B. Eisenberg, and P.J. Roberts Efficacy of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
14. J. Prat Pathology of the ovary 2004 Saunders Philadelphia
15. R.E. Scully, R.H. Young, and P.B. Clement Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of tumor pathology 1996 Armed Forces Institute of Pathology Washington, DC 37
16. Y. Shimizu, S. Kamoi, S. Amada, F. Akiyama, and S.G. Silverberg Toward the development of a universal grading system for ovarian epithelial carcinoma Cancer 82 1998 893 901
17. H. Brustmann Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study Gynecol. Oncol. 92 2004 268 276
18. G. Peiro, J. Diebold, G.B. Baretton, R. Kimmig, and U. Löhrs Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with bcl-2, bax, and caspase-3 expression and outcome Int. J. Gynecol. Pathol. 20 2001 359 367
19. A.K. Sood, J. Coffin, S. Jabbari, R.E. Buller, M.J. Hendrix, and A. Klingelhutz p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma Cancer Biol. Ther. 1 2002 511 517
20. S. Kyo, T. Kanaya, M. Takakura, M. Tanaka, A. Yamashita, and H. Inoue Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors Int. J. Cancer 80 1999 804 809
21. F. Buttitutta, C. Pellegrini, A. Marchetti, A. Gadducci, S. Cosio, and L. Felicioni Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma J. Clin. Oncol. 21 2003 1320 1325
22. G.B. Wisman, H. Hollema, M.N. Helder, A.J. Knol, G.T. Van der Meer, and M. Kraus Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours Int. J. Oncol. 23 2003 1451 1459
23. K. Liu, R.J. Hodes, and N.P. Weng Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation J. Immunol. 166 2001 4826 4830
24. T.W. Park, S. Riethdorf, L. Riethdorf, T. Loning, and F. Janicke Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors Int. J. Cancer 84 1999 426 431
25. J. Liu, G. Yang, J.A. Thompson-Lanza, A. Glassman, K. Hayes, and A. Patterson A genetically defined model for human ovarian cancer Cancer Res. 64 2004 1655 1663
26. A. Baykal, D. Rosen, C. Zhou, J. Liu, and A.A. Sahin Telomerase in breast cancer Adv. Anat. Pathol. 11 2004 262 268
27. A. Widschwendter, H.M. Muller, M.M. Hubalek, A. Wiedemair, H. Fiegl, and G. Goebel Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer Gynecol. Oncol. 93 2004 407 416
28. A.M. Tornary, E.A. Macdonald, W. Faught, M.K. Senterman, and B.C. Vanderhyden Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis Int. J. Cancer 89 2000 242 250
29. J.A. Parrott, G. Kim, and M.K. Skinner Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer Biol. Reprod. 62 2000 1600 1609
30. M. Inoue, S. Kyo, M. Fujita, T. Enomoto, and G. Kondoh Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors Cancer Res. 54 1994 3049 3053
31. E. Wrigley, A.T. McGown, T.H. Ward, C. Ewen, and D. Crowther c-kit receptors in ovarian tumors and the response of ovarian carcinoma cell lines to recombinant human stem cell factor Int. J. Gynecol. Cancer 6 1996 273 278
32. M.R. Raspollini, G. Amunni, A. Villanucci, G. Baroni, A. Taddei, and G.L. Taddei c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study Ann. Oncol. 15 2004 594 597